Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

PHASE2UnknownINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

June 22, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

October 31, 2020

Conditions
Papulopustular Rosacea
Interventions
DRUG

Rifaximin delayed release 400 mg tablet

Rifaximin delayed release

DRUG

Placebo

Placebo

Trial Locations (12)

Unknown

RECRUITING

Ospedali Riuniti di Ancona, Ancona

RECRUITING

Policlinico di Bari, Bari

RECRUITING

Policlinico Sant'Orsola Malpighi, Bologna

RECRUITING

Spedali Civili, Brescia

RECRUITING

Policlinico Vittorio Emanuele, Catania

RECRUITING

Ospedale Policlinico San Martino, Genova

RECRUITING

Ospedale della Misericordia, Grosseto

RECRUITING

Policlinico di Modena, Modena

RECRUITING

Azienda Ospedaliera Universitaria Federico II, Napoli

RECRUITING

Policlinico Universitario A. Gemelli, Roma

RECRUITING

Azienda Ospedaliera Santa Maria, Terni

RECRUITING

A.O.U. Città della Salute e della Scienza, Torino

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alfasigma S.p.A.

INDUSTRY

NCT03864978 - Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test | Biotech Hunter | Biotech Hunter